275 related articles for article (PubMed ID: 14669843)
21. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies.
Endrikat J; Parke S; Trummer D; Schmidt W; Duijkers I; Klipping C
Contraception; 2008 Sep; 78(3):218-25. PubMed ID: 18692612
[TBL] [Abstract][Full Text] [Related]
22. The effect of estradiol valerate and dienogest combination on serum homocysteine levels in postmenopausal women: a clinical trial.
Pirimoglu ZM; Aygun E; Dansuk R; Kucukercan I; Unal O; Turan C
Gynecol Endocrinol; 2005 Sep; 21(3):185-8. PubMed ID: 16335913
[TBL] [Abstract][Full Text] [Related]
23. Identifying target regions for vigilance improvement under hormone replacement therapy in postmenopausal syndrome patients by means of electroencephalographic tomography (LORETA).
Saletu B; Anderer P; Saletu-Zyhlarz GM; Gruber D; Metka M; Huber J
Psychopharmacology (Berl); 2005 Apr; 178(4):389-99. PubMed ID: 15765254
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women.
Gräser T; Koytchev R; Müller A; Oettel M
Climacteric; 2000 Jun; 3(2):109-18. PubMed ID: 11910651
[TBL] [Abstract][Full Text] [Related]
25. Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial.
Raps M; Rosendaal F; Ballieux B; Rosing J; Thomassen S; Helmerhorst F; van Vliet H
J Thromb Haemost; 2013 May; 11(5):855-61. PubMed ID: 23410231
[TBL] [Abstract][Full Text] [Related]
26. Continuous combined hormone replacement therapy relieves climacteric symptoms and improves health-related quality of life in early postmenopausal women.
Pitkin J; Smetnik VP; Vadász P; Mustonen M; Salminen K; Ylikangas S;
Menopause Int; 2007 Sep; 13(3):116-23. PubMed ID: 17785037
[TBL] [Abstract][Full Text] [Related]
27. Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding.
Wasiak R; Filonenko A; Vanness DJ; Law A; Jeddi M; Wittrup-Jensen KU; Stull DE; Siak S; Jensen JT
J Womens Health (Larchmt); 2013 Apr; 22(4):378-84. PubMed ID: 23586801
[TBL] [Abstract][Full Text] [Related]
28. [Association of E2v/DNG as contraceptive choice for a better quality of life of women].
Nappi RE
Minerva Ginecol; 2012 Feb; 64(1):41-52. PubMed ID: 22334230
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
[TBL] [Abstract][Full Text] [Related]
30. Hormone withdrawal-associated symptoms: comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate.
Jensen JT; Parke S; Mellinger U; Serrani M; Mabey RG
Eur J Contracept Reprod Health Care; 2013 Aug; 18(4):274-83. PubMed ID: 23638631
[TBL] [Abstract][Full Text] [Related]
31. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism.
De Leo V; Fruzzetti F; Musacchio MC; Scolaro V; Di Sabatino A; Morgante G
Contraception; 2013 Sep; 88(3):364-8. PubMed ID: 23769016
[TBL] [Abstract][Full Text] [Related]
32. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial.
Fraser IS; Römer T; Parke S; Zeun S; Mellinger U; Machlitt A; Jensen JT
Hum Reprod; 2011 Oct; 26(10):2698-708. PubMed ID: 21784734
[TBL] [Abstract][Full Text] [Related]
33. The effects of postmenopausal hormone replacement therapy and oral contraceptives on the endogenous estradiol metabolism.
Mueck AO; Seeger H; Gräser T; Oettel M; Lippert TH
Horm Metab Res; 2001 Dec; 33(12):744-7. PubMed ID: 11753761
[TBL] [Abstract][Full Text] [Related]
34. A one-year randomized double-blind, multicentre study to evaluate the effects of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate and 2 mg dienogest on metabolism in postmenopausal women.
Endrikat J; Lange E; Kunz M; Schmidt W; Graeser T
Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):229-39. PubMed ID: 17763261
[TBL] [Abstract][Full Text] [Related]
35. Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest.
Fraser IS; Jensen J; Schaefers M; Mellinger U; Parke S; Serrani M
Contraception; 2012 Aug; 86(2):96-101. PubMed ID: 22240178
[TBL] [Abstract][Full Text] [Related]
36. Age-related cognitive decline in the menopause: effects of hormone replacement therapy on cognitive event-related potentials.
Anderer P; Saletu B; Gruber D; Linzmayer L; Semlitsch HV; Saletu-Zyhlarz G; Brandstätter N; Metka M; Huber J
Maturitas; 2005 Jul; 51(3):254-69. PubMed ID: 15978969
[TBL] [Abstract][Full Text] [Related]
37. Effect of different preparations of hormone therapy on sexual dysfunction in naturally postmenopausal women.
Osmanağaoğlu MA; Atasaral T; Baltaci D; Bozkaya H
Climacteric; 2006 Dec; 9(6):464-72. PubMed ID: 17085380
[TBL] [Abstract][Full Text] [Related]
38. Influence of a continuous combined HRT (2 mg estradiol valerate and 2 mg dienogest) on postmenopausal depression.
Rudolph I; Palombo-Kinne E; Kirsch B; Mellinger U; Breitbarth H; Gräser T
Climacteric; 2004 Sep; 7(3):301-11. PubMed ID: 15669555
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: a pooled analysis of three studies conducted in North America and Europe.
Nelson A; Parke S; Makalova D; Serrani M; Palacios S; Mellinger U
Eur J Contracept Reprod Health Care; 2013 Aug; 18(4):264-73. PubMed ID: 23651474
[TBL] [Abstract][Full Text] [Related]
40. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study.
Macìas G; Merki-Feld GS; Parke S; Mellinger U; Serrani M
J Obstet Gynaecol; 2013 Aug; 33(6):591-6. PubMed ID: 23919857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
